EUVIMEDEUVIMED entdecken
Crossref

House dust mite SLIT-tablet is well tolerated in pediatric patients with controlled asthma

Hisashi Tanida, Takayasu Nomura, Yuto Kondo, Yasutaka Hirabayashi, Jun Wakatsuki, Shinji Saitoh

Asian Pacific Journal of Allergy and Immunology · 2025

DOI: 10.12932/ap-051220-1009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Asian Pacific Journal of Allergy and Immunology, 2025. Verfasst von Hisashi Tanida und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Neonatology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan. Hauptthemen laut MEDLINE: Asthma, Sublingual Immunotherapy, Pyroglyphidae.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: : Despite the reported clinical effectiveness of house dust mite (HDM) sublingual immunotherapy (SLIT) in pediatric patients, the risk of treatment remains unclear in pediatric patients with allergic asthma. OBJECTIVE: To show a risk of adverse drug reactions (ADRs) in pediatric patient with allergic asthma during the initiation period of HDM SLIT. METHODS: We retrospectively analyzed the clinical data of pediatric patients aged ≤ 15 years who initiated allergen immunotherapy (AIT) with the SQ HDM SLIT-tablet for allergic rhinitis between February 2017 and September 2019. Asthma severity at baseline and ADRs during the first 4 weeks of the treatment were determined for each subject. RESULTS: In our study population (n = 217; median age, 8.4 years), 99 patients (45.6%) were classified as having asthma. One hundred and one patients (46.5%) in the whole cohort experienced ADRs during the first 4 weeks of therapy, but a major gap in the frequency of ADRs was not observed between an asthma group and a non-asthma group. CONCLUSIONS: The SQ HDM SLIT-tablet was well tolerated in pediatric patients with controlled HDM-driven allergic asthma. HDM-SLIT is an option to treat their allergic rhinitis without excessive concern for its ADRs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaSublingual ImmunotherapyPyroglyphidaeHumansChildMaleFemaleRetrospective StudiesAnimalsAdolescentChild, PreschoolTabletsAntigens, DermatophagoidesTreatment OutcomeRhinitis, Allergic

Substanzen

TabletsAntigens, Dermatophagoides

Autor:innen und Institutionen

  • Department of Pediatrics and Neonatology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
  • Hibarigaoka Kids Allergy Clinic, Nagoya, Japan.
  • Wakatsuki Kids Allergy Clinic, Nagoya, Japan.

Zitieren

APA

Tanida, H., Nomura, T., Kondo, Y., Hirabayashi, Y., Wakatsuki, J., & Saitoh, S. (2025). House dust mite SLIT-tablet is well tolerated in pediatric patients with controlled asthma. Asian Pacific Journal of Allergy and Immunology. https://doi.org/10.12932/ap-051220-1009

Vancouver

Tanida H, Nomura T, Kondo Y, Hirabayashi Y, Wakatsuki J, Saitoh S. House dust mite SLIT-tablet is well tolerated in pediatric patients with controlled asthma. Asian Pacific Journal of Allergy and Immunology. 2025. doi:10.12932/ap-051220-1009

BibTeX
@article{Tanida2025,
  author = {Tanida, Hisashi and Nomura, Takayasu and Kondo, Yuto and Hirabayashi, Yasutaka and Wakatsuki, Jun and Saitoh, Shinji},
  title = {House dust mite SLIT-tablet is well tolerated in pediatric patients with controlled asthma},
  journal = {Asian Pacific Journal of Allergy and Immunology},
  year = {2025},
  doi = {10.12932/ap-051220-1009}
}
Kostenlos starten →